Recruiting studies: Recurrent Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Phase 1 · 3 location(s) · Nerviano Medical Sciences · NCT06931626 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793 Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994 A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Pos
Phase 2 · 34 location(s) · RemeGen Co., Ltd. · NCT06962865 A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase 3 · 126 location(s) · GlaxoSmithKline · NCT07099898 MOv19-BBz CAR T Cells in FRa+ Cancers
Phase 1 · 1 location(s) · University of Pennsylvania · NCT07116057 Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese
NA · 1 location(s) · Shanghai University of Traditional Chinese Medicine · NCT05834413 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-M
Phase 2 · 248 location(s) · SWOG Cancer Research Network · NCT06116682 First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07355205 Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer
Phase N/A · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05424029 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086 Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
NA · 1 location(s) · Chang Gung Memorial Hospital · NCT06262386 Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Phase N/A · 1 location(s) · Samsung Medical Center · NCT03791034 Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623 Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814 An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · ToLymph Inc. · NCT06693336 SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)
NA · 6 location(s) · A.O.U. Città della Salute e della Scienza · NCT05689619 A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors
Phase 1/Phase 2 · 12 location(s) · A2 Biotherapeutics Inc. · NCT06051695 Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Neg
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT05098210 Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Phase 1/Phase 2 · 1 location(s) · Precision Biotech Taiwan Corp. · NCT04616209 Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Phase 3 · 1 location(s) · Luye Pharma Group Ltd. · NCT06496048 Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Phase 2 · 345 location(s) · National Cancer Institute (NCI) · NCT03191149 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Phase 1 · 38 location(s) · Eli Lilly and Company · NCT06465069 Iadademstat + SBRT With Atezo in ES-SCLC
Phase 1 · 1 location(s) · Yale University · NCT07113691 PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT05234307 A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Sta
Phase 3 · 320 location(s) · Bristol-Myers Squibb · NCT06561386 Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810 Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Phase 1/Phase 2 · 11 location(s) · VA Office of Research and Development · NCT06681220 Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung
Phase 2 · 266 location(s) · SWOG Cancer Research Network · NCT06031688 Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung C
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07057102

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →